Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer
Author:
- 30 March 2020
- journal article
- research article
- Published by National Institute of Public Health, Prague in Central European Journal of Public Health
- Vol. 28 (1) , 53-58
Abstract
Objective: This article reviews the published studies dealing with the influence of cigarette smoking on metabolic changes and effectiveness of drugs used in the systemic chemotherapy of the lung cancer. Methods: The literature search of inter...Keywords
This publication has 39 references indexed in Scilit:
- Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case ReportCase Reports in Oncology, 2013
- Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)Journal of Thoracic Oncology, 2012
- Evaluating Smoking Cessation Interventions and Cessation Rates in Cancer Patients: A Systematic Review and Meta-AnalysisISRN Oncology, 2011
- Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapyPharmacogenomics and Personalized Medicine, 2011
- Prognostic factors for limited-stage small cell lung cancer: A study of 284 patientsLung Cancer, 2010
- Drug interactions with smokingAmerican Journal of Health-System Pharmacy, 2007
- Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patientsLung Cancer, 2006
- Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy RegimenClinical Cancer Research, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999